How Breast Cancer Can Affect Your Heart — During Treatment and Beyond

Why It Matters

Cardiovascular disease is the leading cause of death among women, and treatment‑related heart injury can outweigh cancer recurrence risk, making cardiac safety a critical component of breast‑cancer care.

Key Takeaways

• Radiation can damage heart; techniques reduce exposure
• Anthracycline chemo may cause reversible cardiomyopathy
• HER2 therapies lower ejection fraction, monitored via echo
• Hormone therapy alters blood pressure, cholesterol, clot risk
• Multidisciplinary care essential for cardiac monitoring during treatment

Pulse Analysis

Survival rates for breast cancer have improved dramatically, shifting clinical focus toward long‑term health outcomes. Women already bear a disproportionate burden of heart disease, and emerging data show that breast‑cancer therapies can amplify this risk. Studies link chest‑wall radiation and anthracycline chemotherapy to structural heart changes, while HER2‑targeted agents may transiently depress ejection fraction. Recognizing these connections, major cancer centers now embed cardiac risk assessments into treatment planning, using baseline echocardiograms and periodic imaging to catch early dysfunction.

The mechanisms behind therapy‑induced cardiotoxicity vary. Radiation can scar myocardial tissue, especially at high doses, prompting modern techniques such as deep‑inspiration breath‑hold and proton therapy to spare the heart. Anthracyclines generate oxidative stress that weakens cardiac muscle, a risk that rises with cumulative dosing; dose‑limiting strategies and liposomal formulations mitigate exposure. HER2 inhibitors interfere with cardiac signaling pathways, often causing reversible drops in pump function, which clinicians track through serial ejection‑fraction measurements. Hormone therapies, particularly aromatase inhibitors, may elevate blood pressure and cholesterol, while tamoxifen carries a clotting risk, underscoring the need for coordinated primary‑care oversight.

Proactive, multidisciplinary care is the cornerstone of protecting heart health during breast‑cancer treatment. Oncologists, cardiologists, and primary physicians collaborate to tailor regimens based on individual risk profiles, and cardio‑oncology clinics provide specialized monitoring for high‑risk patients. Lifestyle interventions—regular aerobic exercise, a Mediterranean‑style diet, smoking cessation, and moderated alcohol intake—further reduce cardiovascular strain. As survivorship programs evolve, integrating cardiac surveillance into standard protocols ensures that extending life does not come at the expense of heart health.